Table 1.

Emerging topical treatments for HS

Drug name (MOA)	Author or clinical trial #	Study type	Study goal and primary endpoint(s)	Patients enrolled	(Anticipated) completion date	Results or recruitment status
Ruxolitinib 1.5% cream (JAK 1/2 inhibitor)	NCT05635838	Phase 2 randomized, double-blind vehicle-controlled	Evaluate efficacy in patients with mild to moderate HS Endpoint: change from baseline in AN count at week 16	60	March 2024	Recruiting
Ruxolitinib 1.5% cream (JAK 1/2 inhibitor)	NCT04414514	Phase 2 open label	Evaluate efficacy and effects on skin inflammation in patients with HS Endpoint: percentage of patients who achieve HiSCR at week 16	24	January 2025	Recruiting
AT193 (aryl hydrocarbon agonist)	NCT04989517	Phase 1 randomized, double-blind placebo-controlled	Evaluate safety and tolerability in patients with HS Endpoint: incidence of TEAEs up to week 10	44	February 2023	Active, not recruiting
LTX-109 3% gel (lytic peptidomimetic)	NCT04756336	Phase 2 proof of concept	Evaluate safety and efficacy in patients with HS Endpoints: investigator and patient assessed signs and symptoms, respectively, of local reactions to the product until week 6	11	July 2021	Completed
Gentian violet (antiseptic)	NCT04388163	Phase 2 open-label	Evaluate efficacy in patients with HS Endpoint: skin redness, drainage, and pain at baseline and 1 month post-treatment	16	December 2023	Not yet recruiting
Povidone-iodine cream (antimicrobial)	NCT01818167	Prospective multi-center blinded, randomized, controlled clinical trial	Compare efficacy of povidone-iodine topical cream to 10% benzoyl peroxide topical body wash for the treatment of early stage HS Endpoint: HS European Research Group scale up to 4 months	25	January 2015	Results submitted

AN abscesses and inflammatory nodules, HiSCR hidradenitis suppurativa clinical response, HS hidradenitis suppurativa, JAK Janus kinase, MOA mechanism of action, TEAEs treatment emergent adverse events